The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses

Molecular Cancer Therapeutics

Volumn 14, Issue 5, 2015, Pages 1181-1191

  Christiansson, Lisa ^a   Söderlund, Stina ^b,c   Mangsbo, Sara ^a   Hjorth Hansen, Henrik ^d,e   Höglund, Martin ^b,c   Markevärn, Berit ^f   Richter, Johan ^g   Stenke, Leif ^h   Mustjoki, Satu ⁱ   Loskog, Angelica ^a   Olsson Strömberg, Ulla ^b,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CD11B ANTIGEN; CD14 ANTIGEN; CD33 ANTIGEN; CD40 ANTIGEN; DASATINIB; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMATINIB; INTERLEUKIN 10; INTERLEUKIN 12; MYELOPEROXIDASE; CD33 PROTEIN, HUMAN; ITGAM PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ANEMIA; ANTIGEN EXPRESSION; BONE MARROW CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; EX VIVO STUDY; FEMALE; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VIVO STUDY; LEUKOPENIA; LYMPHOCYTE; MALE; MIDDLE AGED; MONOCYTE; MYELOID SUPPRESSOR CELL; NATURAL KILLER CELL; PLEURA EFFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; THROMBOCYTOPENIA; DRUG EFFECTS; IMMUNOLOGY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; PATHOLOGY;

ADULT; AGED; ANTIGENS, CD11B; ANTIGENS, CD14; DASATINIB; FEMALE; HUMANS; IMATINIB MESYLATE; KILLER CELLS, NATURAL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MYELOID CELLS; PROTEIN KINASE INHIBITORS; SIALIC ACID BINDING IG-LIKE LECTIN 3; T-LYMPHOCYTES;

EID: 84938774366     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0849     Document Type: Review

References (37)

1. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeuticmodalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013;19:5300-9.
2. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
3. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates Tlymphocyte cell-cycle progression. Blood 2007;109:1568-73.
4. Zhu J, Huang X, Yang Y. Myeloid-derived suppressor cells regulate natural killer cell response to adenovirus-mediated gene transfer. J Virol 2012;86:13689-96.
5. Tadmor T, Attias D, Polliack A. Myeloid-derived suppressor cells-their role in haemato-oncological malignancies and other cancers and possible implications for therapy. Br J Haematol 2011;153:557-67.
6. Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. Regulatory T cells in cancer. Adv Cancer Res 2010;107:57-117.
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
8. Golovina TN, Vonderheide RH. Regulatory T cells: overcoming suppression of T-cell immunity. Cancer J 2010;16:342-7.
9. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinibmediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148-57.
10. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009;69:2506-13.
11. Sayed D, Badrawy H, Gaber N, Khalaf MR. p-Stat3 and bcr/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy. Leuk Res 2014;38:243-50.
12. Michels S, TrautmannM, Sievers E, Kindler D, Huss S, RennerM, et al. SRC signaling is crucial in the growth of synovial sarcoma cells. Cancer Res 2013;73:2518-28.
13. Steegmann JL, Cervantes F, le Coutre P, Porkka K, Saglio G. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma 2012;53:2351-61.
14. Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005;105:2473-9.
15. Blake SJ, Bruce Lyons A, Fraser CK, Hayball JD, Hughes TP. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008;111:4415-6.
16. Appel S, Boehmler AM, Grunebach F, Muller MR, Rupf A, Weck MM, et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 2004;103:538-44.
17. Chen CI, Maecker HT, Lee PP. Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood 2008;111:5342-9.
18. Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 2010;85:387-98.
19. Mustjoki S, EkblomM, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398-405.
20. Hjorth-Hansen H, Stenke L, Söderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, et al. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomized phase-2 study (NordCML006). Eur J Haematol 2015;94:243-50.
21. Christiansson L, Söderlund S, Svensson E, Mustjoki S, Bengtsson M, Simonsson B, et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS ONE 2013;8:e55818.
22. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicincyclophosphamide chemotherapy. Cancer Immunol Immunother 2009;58:49-59.
23. Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, et al. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood 2012;120:3030-8.
24. Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, et al. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer 2011;129:2158-70.
25. Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010;116:772-82.
26. Kreutzman A, Ilander M, Porkka K, Vakkila J, Mustjoki S. Dasatinib promotes Th1-type responses in granzyme B expressing T-cells. Oncoimmunology 2014;3:e28925.
27. HuangH, Langenkamp E, Georganaki M, Loskog A, Fuchs PF, Dieterich LC, et al. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF.kB-induced endothelial activation. FASEB J 2015;29:227-38.
28. Lowe DB, Bose A, Taylor JL, Tawbe H, Lin Y, Kirkwood JM, et al. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology 2014;3:e27589.
29. Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatibib. Clin Cancer Res 2008;14:2484-91.
30. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008;111:1366-77.
31. Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang G, Yin B, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010;70:99-108.
32. Loskog AS, Eliopoulos AG. The Janus faces of CD40 in cancer. Semin Immunol 2009;21:301-7.
33. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011;17:1094-100.
34. Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res 2013;73:3499-510.
35. Cavnar MJ, Zeng S, Kim TS, Sorenson EC, Ocuin LM, Balachandran VP, et al. KIT oncogene inhibition drives intratumoral macrophage M2 polarization. J Exp Med 2013;210:2873-86.
36. Usuki K, Yokoyama K, Nagamura-Inoue T, Ito A, Kida M, Izutsu K, et al. CD8 +memory T cells predominate over naive T cells in therapy-free CML patients with sustained major molecular response. Leuk Res 2009;33:e164-165.
37. Sgadari C, Farber JM, Angiolillo AL, Liao F, Teruya-Feldstein J, Burd PR, et al. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 1997;89:2635-43.